These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22957898)

  • 41. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT.
    Chiaravalloti A; Danieli R; Caracciolo CR; Travascio L; Cantonetti M; Gallamini A; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
    Medicine (Baltimore); 2014 Aug; 93(8):e50. PubMed ID: 25121354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positron emission tomography for detection and staging of malignant lymphoma.
    Buchmann I; Moog F; Schirrmeister H; Reske SN
    Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of
    Panebianco M; Bagni O; Cenfra N; Mecarocci S; Ortu La Barbera E; Filippi L; Codacci-Pisanelli G; Biondi T; Laghi A; Cimino G
    Leuk Res; 2019 Jan; 76():48-52. PubMed ID: 30553980
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients.
    Miller E; Metser U; Avrahami G; Dvir R; Valdman D; Sira LB; Sayar D; Burstein Y; Toren A; Yaniv I; Even-Sapir E
    J Comput Assist Tomogr; 2006; 30(4):689-94. PubMed ID: 16845304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [PET/CT Image Values in Clinical Staging of the Patients with Non-Hodgkin's Lymphoma].
    Tang HJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1030-3. PubMed ID: 26314440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Non-Hodgkin's lymphoma staging: a prospective study of the value of positron emission tomography/computed tomography (PET/CT) versus PET and CT].
    Rodríguez-Vigil Junco B; Gómez León N; Pinilla Fernández I; del Campo L; Hernández Maraver D; Coya J
    Med Clin (Barc); 2011 Oct; 137(9):383-9. PubMed ID: 21703647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Ann Nucl Med; 2015 Feb; 29(2):132-7. PubMed ID: 25348549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
    Tirumani SH; LaCasce AS; Jacene HA
    PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
    Newman JS; Francis IR; Kaminski MS; Wahl RL
    Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L; Madero R
    J Nucl Med; 2006 Oct; 47(10):1643-8. PubMed ID: 17015900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
    van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
    J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.
    Grellier JF; Vercellino L; Leblanc T; Merlet P; Thieblemont C; Weinmann P; Toubert ME; Berenger N; Brière J; Brice P
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2023-30. PubMed ID: 24965842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.
    Partridge S; Timothy A; O'Doherty MJ; Hain SF; Rankin S; Mikhaeel G
    Ann Oncol; 2000 Oct; 11(10):1273-9. PubMed ID: 11106116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.